Related Experiment Video
Updated: Feb 22, 2026

Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
Published on: November 21, 2024
Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and
Sebastian Bauer1, Natascha van Alphen2, Albert Becker3
1Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, Center of Neurology and Neurosurgery, Goethe University Frankfurt, 60528 Frankfurt, Germany; Epilepsy Center Marburg, Department of Neurology, Philipps-University Marburg, 35043 Marburg, Germany; Center for Personalized Translational Epilepsy Research (CePTER), 60528 Frankfurt, Germany(1).
Abstract:
Despite the availability of more than 15 new "antiepileptic drugs", the proportion of patients with pharmacoresistant epilepsy has remained constant at about 20-30%. Furthermore, no disease-modifying treatments shown to prevent the development of epilepsy following an initial precipitating brain injury or to reverse established epilepsy have been identified to date. This is likely in part due to the polyetiologic nature of epilepsy, which in turn requires personalized medicine approaches. Recent advances in imaging, pathology, genetics, and epigenetics have led to new pathophysiological concepts and the identification of monogenic causes of epilepsy. In the context of these advances, the First International Symposium on Personalized Translational Epilepsy Research (1st ISymPTER) was held in Frankfurt on September 8, 2016, to discuss novel approaches and future perspectives for personalized translational research. These included new developments and ideas in a range of experimental and clinical areas such as deep phenotyping, quantitative brain imaging, EEG/MEG-based analysis of network dysfunction, tissue-based translational studies, innate immunity mechanisms, microRNA as treatment targets, functional characterization of genetic variants in human cell models and rodent organotypic slice cultures, personalized treatment approaches for monogenic epilepsies, blood-brain barrier dysfunction, therapeutic focal tissue modification, computational modeling for target and biomarker identification, and cost analysis in (monogenic) disease and its treatment. This report on the meeting proceedings is aimed at stimulating much needed investments of time and resources in personalized translational epilepsy research. This Part II includes the experimental and translational approaches and a discussion of the future perspectives, while the diagnostic methods, EEG network analysis, biomarkers, and personalized treatment approaches were addressed in Part I [1].
Insights
Personalized translational research is crucial for advancing epilepsy treatment, given the constant rate of pharmacoresistant epilepsy. Novel experimental and clinical approaches are needed to develop effective, individualized therapies for epilepsy.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Pharmacoresistant epilepsy affects 20-30% of patients despite new drugs.
- Current treatments do not prevent epilepsy development or reverse established disease.
- Epilepsy's complex causes necessitate personalized medicine strategies.
Purpose of the Study:
- To discuss novel approaches and future perspectives for personalized translational epilepsy research.
- To highlight advancements in experimental and clinical areas relevant to epilepsy.
- To stimulate investment in personalized translational epilepsy research.
Main Methods:
- Deep phenotyping
- Quantitative brain imaging
- EEG/MEG-based network analysis
- Tissue-based translational studies
- Innate immunity research
- microRNA targeting
- Genetic variant functional characterization
- Monogenic epilepsy treatment approaches
- Blood-brain barrier research
- Focal tissue modification
- Computational modeling
- Cost-effectiveness analysis
Main Results:
- Advances in imaging, genetics, and epigenetics are revealing new epilepsy concepts.
- Identification of monogenic causes enables targeted research.
- A wide range of experimental and clinical strategies were discussed for personalized epilepsy research.
Conclusions:
- Personalized translational research is essential for overcoming challenges in epilepsy treatment.
- Further investment is needed to translate research findings into clinical practice.
- Future research should focus on individualized approaches for diverse epilepsy etiologies.

